Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-06-05
1998-09-15
Rotman, Alan L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544396, A61K 31495, C07D24104
Patent
active
058078584
ABSTRACT:
The present invention relates to, inter alia, methods and compositions for reducing, treating or preventing respiratory depression in an animal, using a compound of the formula: ##STR1## wherein: Ar, G, Z, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined in specification,
or a pharmaceutically acceptable ester or salt thereof.
REFERENCES:
patent: 2630435 (1953-03-01), Baltzly et al.
patent: 4518711 (1985-05-01), Hruby et al.
patent: 4816586 (1989-03-01), Portoghese
patent: 5574159 (1996-11-01), Chang et al.
Comer, "BW373U86: Behavioral Pharmacology of a Putative Non-Peptide, Systemically-Active Delta Opioid Agonist," Dissertation Abstracts International, 53(5B). 2578 (Jul. 1, 1992--entered in the University of Michigan on-line catalog).
Pakarinen, E.D., "Effects of Convulsant Agents on Learning and Memory in Squirrel Monkeys," Dissertation Abstracts International, 54(O1B), 189 (Mar. 31, 1993--entered in the Louisiana State University on-line catalog).
Selley, "BW373U86 A Non-peptide .differential.-Opioid Agonist With Novel Receptor-G-Protein-Mediated Actions," Meeting of the International Narcotics Research Conference (INRC). Skoevde, Sweden, Abstract (Jul. 11-16, 1993).
Calderon, S.N. et al., "Synthesis and Absolute Configuration of Optically Pure Enantiometers of (=)-BW373U86, A Nonpeptide .differential.-Opioid Receptor Agonist," College on Problems of Drug Dependence, Inc., Fifty-fifth Annual Scientific Meeting, Toronto, Canada, Poster Presentation. (Jun. 12-17, 1993).
Chang, "Identification of a Novel, Potent and Selective Non-Peptidic Delta-selective Agonist BW373U86," Meeting of the International Narcotics Research Conference (INRC). Keystone, Colorado, Oral Presentation, (Jun. 23-27, 1992).
Comer, "BW373U86: Delta-receptor-mediation of Convulsions and Refractoriness," Meeting of the International Narcotics Research Conference (INRC). Keystone, Colorado, Oral Presentation, (Jun. 23-27, 1992).
Dykstra, "Behavioral Effects of a Novel and Selective Opioid Delta Agonist in the Monkey," Meeting of the International Narcotics Research Conference (INRC). Keystone, Colorado, Oral Presentation, (Jun. 23-27, 1992).
Porreca, "Multiple Opioid Delta Receptors," Meeting of the International Narcotics Research Conference (INRC). Keystone, Colorado, Oral Presentation, (June23-27, 1992).
Broadbent et al., "Role of Opioid Receptor Subtypes in the Discriminative Stimulus Effects of Cocaine," Meeting of the International Narcotics Research Conference (INRC). Keystone, Colorado, Abstract, (Jun. 23-27, 1992).
Dworkin et al., "Effects of .differential.-Opiate Agonists and Antagonists on Cocaine and Heroin Self Administration in Rats," Meeting of the International Narcotics Research Conference (INRC). Keystone, Colorado, Abstract, (Jun. 23-27, 1992).
Dykstra et al., "Effects of a Novel Delta Opioid Agonist in Squirrel Monkeys Responding Under a Schedule of Shock Titration," Meeting of the International Narcotics Research Conference (INRC). Keystone, Colorado, Abstract, (Jun. 23-27, 1992).
Lee et al., "A Non-peptide Delta-Opioid Receptor Agonist BW373U86 Suppresses Naloxone-precipated Morphine Abstinence," Meeting of the International Narcotics Research Conference (INRC). Keystone, Colorado, Abstract, (Jun. 23-27, 1992).
Porreca et al., "Pharmacology of Multiple Opioid Delta Receptors," National Institute on Drug Abuse Research Monograph Series 132, Problems of Drug Dependence, 1992: Proceeding of the 54th Annual Scientific Meeting, 430-436 (1993).
Iwamoto et al., "Calcium Antagonism, by KB-2796, a New Diphenylpiperazine analogue, in Dog Vascular Smooth Muscle," J. Pharm. Pharmocol., 43, 535-539 (1991).
Goenechea et al., "Untersuchengen zur Biotransformation von Meclozin im Menschlichen Korper," J. Clin. Chem. Clin. Biochem., 26, 105-115 (1988)--See specification, p. 4, last paragraph and Chemical Abstracts 108: 215746g.
Iwamoto et al., "effects of KB-2796, a New Calcium Antagonist, and Other Pharmacol., 48, 241-247 (1988).
Natsuka et al., "Synthesis and Structure-Activity Relationships of 1-Substituted 4-(1,2-Diphenylethyl)piperazine Derivatives having Narcotic Agonist and Antagonist Activity," J. Med. Chem., 30(10), 1779-1787 (1987).
Meuldermas et al., "Plasma Levels, Biotransformation and Excretion of Oxatomide (R 35 443) in Rats, Dogs and Man," Xenobiotica, 14(6), 445-462 (1984).
Krishnamurthy, "A Highly Efficient and General N-Monomethylation of Functionalized Primary Amines Via Formylation-Borane: Methyl Sulfide Reduction," Tet. Let., 23(33), 3315-3318 (1982).
Lord, et al., "Endogenous Opioid Peptides: Multiple Agonists and Receptors," Nature, 267, 495-499 (1977).
Chang, et al., "A Novel Potent and Selective Nonpeptide Delta Opioid Receptor Agonist BW373U86," J. Pharmacol. Exp. Ther., 267, 852-857 (1993).
Childers, et al., "BW373U86: A Non-peptidic .differential.-Opioid Agonist With Novel Receptor-g Protein-mediated Actions in Rat Brain Membranes and Neuroblastoma Cells," Molec. Pharmacol., 44, 827-834 (1993).
Comer, et al., "Convulsive Effects of Systemic Administration of the Delta Opioid Agonist BW373U86 in Mice," J. Pharmacol. Exp. Ther., 267, 888-895 (1993).
Comer, et al., "Discriminative stimulus Effects of BW373U86: A Non-peptide Ligand With Selectivity for Delta Opioid Receptors," J. Pharmacol. Exp. Ther., 267, 866-874 (1993).
Dykstra, et al., "A Novel Delta Opioid Agonist, BW373U86, in Squirrel Monkeys Responding Under a Schedule of Shock Titration," J. Pharmacol. Exp. Ther., 267, 875-882 (1993).
Lee, et al., "A Nonpeptidic Delta-opioid Receptor Agonist, BW373U86, Attenuates the Development and Expression of Morphine Abstinence Precipitated by Naloxone in Rat . . . ," J. Pharmacol. Exp. Ther., 267, 896-903 (1993).
Negus et al., "Effects of Opioid Agonists Selective for Mu, Kapa and Delta Opioid Receptors on Schedule-controlled Responding in Rhesus Monkeys: Antagonism by Quadazocine," J. Pharmacol. Exp. Ther., 267, 896-903 (1993).
Wild, et al., "Binding of 373U86, A Non-peptidic .differential.-Opioid Receptor Agonist, is Not Regulated by Guanine Nucleotides and Sodium," Eur. J. Pharmacol.-Molec. Pharmacol., Section 246, 289-292 (1993).
Wild, et al., "Antinociceptive Actions of BW373U86 in the Mouse," J. Pharmacol., Exp. Ther. 267, 858-865, 1993.
Xu, et al., "Differential Binding of Opioid Peptides and Other Drugs to Two Subtypes of Opioid .differential..sub.ncx Binding Sites in Mouse Brain: Further Evidence of .differential. Receptor Heterogeneity," Peptides 14, 893-907 (1993).
Campa, et al., "Characterization of .differential. Opioid Receptors in Lung Cancer Using a Novel Nonpeptidic Ligand," Cancer Research 56, 1965-1701, 1996.
Bishop Michael J.
Chang Kwen-Jen
McNutt, Jr. Robert W.
Pettit Hugh O.
Aulakm Charanjit S.
Barrett William A.
Delta Pharmaceutical, Inc.
Hultquist Steven J.
Rotman Alan L.
LandOfFree
Compositions and methods for reducing respiratory depression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for reducing respiratory depression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for reducing respiratory depression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-87501